VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Tannir on Sunitinib Plus Temsirolimus for mRCC

Nizar M. Tannir, MD, FACP
Published: Wednesday, Feb 12, 2014

Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

This combination was previously studied, though was found to be “not viable,” Tannir says. The question remained as to whether these drugs should be tested in combination again.

This phase I trial took a long time to accrue 20 patients, Tannir says, though it was found that these drugs could be combined. Researchers found that temsirolimus must be reduced to 8 or 10 mg weekly in order to maintain the 37.5-mg dosing of sunitinib.

Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

This combination was previously studied, though was found to be “not viable,” Tannir says. The question remained as to whether these drugs should be tested in combination again.

This phase I trial took a long time to accrue 20 patients, Tannir says, though it was found that these drugs could be combined. Researchers found that temsirolimus must be reduced to 8 or 10 mg weekly in order to maintain the 37.5-mg dosing of sunitinib.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x